Erratum : Heart failure, saxagliptin, and diabetes mellitus: Observations from the SAVOR-TIMI 53 randomized trial (Circulation (2014), 130, (1579-1588)) doi:10.1161/CIRCULATIONAHA.114.010389;Heart failure, saxagliptin, and diabetes mellitus: Observations from the SAVOR-TIMI 53 randomized trial

Circulation

Volumn 130, Issue 18, 2014, Pages 1579-1588

  Scirica, Benjamin M ^a   Braunwald, Eugene ^a   Raz, Itamar ^b   Cavender, Matthew A ^a   Morrow, David A ^a   Jarolim, Petr ^a   Udell, Jacob A ^c   Mosenzon, Ofri ^b   Im, Kyungah ^a   Umez Eronini, Amarachi A ^a   Pollack, Pia S ^d   Hirshberg, Boaz ^d   Frederich, Robert ^e   Lewis, Basil S ^f   McGuire, Darren K ^g   Davidson, Jaime ^h   Steg, Ph Gabriel ^i,j   Bhatt, Deepak L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c UNIVERSITY OF TORONTO   (Canada)

^d ASTRAZENECA   (United Kingdom)

^e BRISTOL MYERS SQUIBB   (United States)

^f TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^g Cardiovascular Medicine   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ UNIVERSITÉ PARIS DESCARTES   (France)

^j ROYAL BROMPTON HOSPITAL   (United Kingdom)

more..

Author keywords

Diabetes mellitus; Heart failure; Saxagliptin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALBUMIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; PLACEBO; SAXAGLIPTIN; SULFONYLUREA; TROPONIN T; VASODILATOR AGENT; ADAMANTANE; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DEATH; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIURETIC THERAPY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT DURATION; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; COMPLICATION; DIABETES MELLITUS, TYPE 2; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK ASSESSMENT;

ADAMANTANE; AGED; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RISK ASSESSMENT; TROPONIN T;

EID: 84917723836     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIR.0000000000000330     Document Type: Erratum

References (42)

1. McMurray JJV, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol. March 13, 2014. doi: 10.1016/S2213- 8587(14)70031-2. http://thelancet.com. Accessed August 27, 2014.
2. Rodrigues B, Cam MC, McNeill JH. Myocardial substrate metabolism: implications for diabetic cardiomyopathy. J Mol Cell Cardiol. 1995; 27: 169-179.
3. Opie LH, Yellon DM, Gersh BJ. Controversies in the cardiovascular management of type 2 diabetes. Heart. 2011; 97: 6-14.
4. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation. 2007; 115: 3213-3223.
5. Schilling JD, Mann DL. Diabetic cardiomyopathy: bench to bedside. Heart Fail Clin. 2012; 8: 619-631.
6. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care. 2001; 24: 1614-1619.
7. Bhatt DL, Chew DP, Grines C, Mukherjee D, Leesar M, Gilchrist IC, Corbelli JC, Blankenship JC, Eres A, Steinhubl S, Tan WA, Resar JR, AlMahameed A, Abdel-Latif A, Wilson Tang WH, Tang HW, Brennan D, McErlean E, Hazen SL, Topol EJ. Peroxisome proliferator-activated receptor gamma agonists for the prevention of adverse events following percutaneous coronary revascularization-results of the PPAR study. Am Heart J. 2007; 154: 137-143.
8. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lef?bvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366: 1279-1289.
9. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007; 370: 1129-1136.
10. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005; 294: 2581-2586.
11. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009; 373: 2125-2135.
12. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005; 28: 2345-2351.
13. Nichols GA, Koro CE, Gullion CM, Ephross SA, Brown JB. The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev. 2005; 21: 51-57.
14. Eurich DT, McAlister FA, Blackburn DF, Majumdar SR, Tsuyuki RT, Varney J, Johnson JA. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ. 2007; 335: 497.
15. Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, Vanderloo SE, McAlister FA. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34, 000 patients. Circ Heart Fail. 2013; 6: 395-402.
16. Roussel R, Travert F, Pasquet B, Wilson PW, Smith SC Jr, Goto S, Ravaud P, Marre M, Porath A, Bhatt DL, Steg PG; Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med. 2010; 170: 1892-1899.
17. Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, Selby JV. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001; 103: 2668-2673.
18. Inzucchi SE, McGuire DK. New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. Circulation. 2008; 117: 574-584.
19. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Price DL, Chen R, Udell J, Raz I. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. Am Heart J. 2011; 162: 818-825.e6.
20. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369: 1317-1326.
21. Hicks KA, Hung HMJ, Mahaffey KW, Mehran R, Nissen SE, Stockbridge NL, Targum SL, Temple R. Standardized definitions for end point events in cardiovascular trials. 2010. https://www.dcri.org/education-training/meetings/meeting-brochures/parc-meeting-materials/february-3rd-2012/articles/Standardized%20Definitions.pdf/view.
22. Giannitsis E, Becker M, Kurz K, Hess G, Zdunek D, Katus HA. Highsensitivity cardiac troponin T for early prediction of evolving non-STsegment elevation myocardial infarction in patients with suspected acute coronary syndrome and negative troponin results on admission. Clin Chem. 2010; 56: 642-650.
23. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Statistics. 1982; 10: 1100-1120.
24. Prentice RL, Williams BJ, Petersen V. On the regression analysis of multivariate failure time data. Biometrika 1981; 68: 373-379.
25. Gray RJ. Flexible methods for analyzing survival data using splines, with applications to breast cancer prognosis. J Am Stat Assoc. 1992; 87: 942-951.
26. Khan MA, Deaton C, Rutter MK, Neyses L, Mamas MA. Incretins as a novel therapeutic strategy in patients with diabetes and heart failure. Heart Fail Rev. 2013; 18: 141-148.
27. McMurray JJ, Ponikowksi P, Bolli GB, Kozlovski P, Jhund P, Lewsey JD, Moeckel V, Lukashevich V, Kothny W, Krum H. Vildagliptin in Ventricular Dysfunction Diabetes Trial (VIVIDD). Eur J Heart Fail. 2013; 12.
28. Iqbal N, Parker A, Frederich R, Donovan M, Hirshberg B. Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials. Cardiovasc Diabetol. 2014; 13: 33.
29. Ayaori M, Iwakami N, Uto-Kondo H, Sato H, Sasaki M, Komatsu T, Iizuka M, Takiguchi S, Yakushiji E, Nakaya K, Yogo M, Ogura M, Takase B, Murakami T, Ikewaki K. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients. J Am Heart Assoc. 2013; 2: e003277.
30. White WB. Cardiovascular outcomes with alogliptin in patients with type 2 diabetes mellitus and recent acute coronary syndromes. European Association for the Study of Diabetes. Barcelona2013. April 3, 2014. http://www.easdvirtualmeeting.org/resources/7109. Accessed September 16, 2014.
31. Lincoff AM, Tardif JC, Schwartz GG, Nicholls SJ, Rydén L, Neal B, Malmberg K, Wedel H, Buse JB, Henry RR, Weichert A, Cannata R, Svensson A, Volz D, Grobbee DE; AleCardio Investigators. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA. 2014; 311: 1515-1525.
32. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassa? B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: metaanalysis of randomised controlled trials. BMJ. 2011; 343: d4169.
33. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009; 373: 1765-1772.
34. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352: 854-865.
35. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352: 837-853.
36. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358: 2560-2572.
37. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358: 2545-2559.
38. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360: 129-139.
39. Dutka DP, Pitt M, Pagano D, Mongillo M, Gathercole D, Bonser RS, Camici PG. Myocardial glucose transport and utilization in patients with type 2 diabetes mellitus, left ventricular dysfunction, and coronary artery disease. J Am Coll Cardiol. 2006; 48: 2225-2231.
40. Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, Grimm RH Jr, Byington RP, Rosenberg YD, Friedewald WT. Long-term effects of intensive glucose lowering on cardiovascular outcomes. New Engl J Med. 2011; 364: 818-828.
41. McGuire DK, Abdullah SM, See R, Snell PG, McGavock J, Szczepaniak LS, Ayers CR, Drazner MH, Khera A, de Lemos JA. Randomized comparison of the effects of rosiglitazone versus placebo on peak integrated cardiovascular performance, cardiac structure, and function. Eur Heart J. 2010; 31: 2262-2270.
42. Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Ryden LE, Yusuf S. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012; 367: 319-328.